The Ministry of Sanitation and Welfare promulgated Articles 2 and 5 of the Rules for Medical Subsidies for Rare Disorders (hereinafter, the "Rules") as amended via the Bu-Shou-Guo-1040400442 Circular of March 6, 2015.
Article 2 provides for the following medical expenses arising from rare disorders which are assumed by rare disorder patients, including: (1) expenses relating to diagnosis having major impact on the treatment methods or hereditary counseling and recommendation for rare disorders; (2) expenses relating to treatments and drugs with appropriate medicinal effects and safety characteristics and special nutrients required for the sustenance of life as verified by domestic and overseas research and as determined by the Rare Disorder and Medicine Review Committee; (3) examination expenses for diagnosisto confirm suspicious rare disorders; (4) expenses for nutritional counseling for metabolic rare disorders; (5) expenses for home care medical devices required for maintenance of life; (6) expenses for confirmation diagnosis of blood relatives within four degrees of consanguinity who are suspected to have contracted or be prone to rare disorders; and (7) the cost of the medicine for rare disorders determined by the Rare Disorder and Medicine Review Committee and announced by the central competent authority before such medicine can be included in the coverage of the National Health Insurance Program according to the incorporation procedure under the National Health Insurance Drug Reimbursement Items and Standards. However, the costs and expenses should be limited to those which have been recognized by the Rare Disorder and Medicine Review Committee. Application may be filed to subsidize such expenses pursuant to the Rules, except for those for which other subsidies have been applied.
Article 5, Paragraph 1 of the Rules stipulates the criteria for all kinds of subsidies and their ceilings. Paragraph 2 provides that application for the subsidies shall be filed with the central competent authority by the medical institution that provides the treatment along with relevant supporting documents within three years after the rare disorder medicine is recognized by the Rare Disorder and Medicine Review Committee and announced by the central competent authority. The subsidies will be capped at 80% and the maximum subsidy for each case shall not exceed NT$500,000 each month.